Fineline Cube

Follow:
14691 Articles
CSPC's Recombinant Herpes Zoster Vaccine SYS6052 Clears U.S. FDA IND – Company's First Recombinant Protein Vaccine Candidate to Enter Clinical Trials
CompanyDrug

CSPC’s Recombinant Herpes Zoster Vaccine SYS6052 Clears U.S. FDA IND – Company’s First Recombinant Protein Vaccine Candidate to Enter Clinical Trials

China's CDE Launches "Pioneer Plan" Pilot to Advance New Approach Methodologies (NAMs) in Non‑Clinical Drug Evaluation – Aiming to Reduce, Refine, and Replace Animal Testing
Policy / Regulatory

China’s CDE Launches “Pioneer Plan” Pilot to Advance New Approach Methodologies (NAMs) in Non‑Clinical Drug Evaluation – Aiming to Reduce, Refine, and Replace Animal Testing

GenFleet's Oral KRAS G12D Inhibitor GFH375 Wins Third NMPA Breakthrough Therapy Designation – Combination with Cetuximab for Pretreated Metastatic Colorectal Cancer
CompanyDrug

GenFleet’s Oral KRAS G12D Inhibitor GFH375 Wins Third NMPA Breakthrough Therapy Designation – Combination with Cetuximab for Pretreated Metastatic Colorectal Cancer

Dizal Receives $600 Million Upfront Payment from AstraZeneca as Global Sunvozertinib License Takes Effect – Only Dual‑Approved Oral TKI for EGFR Exon20ins NSCLC
CompanyDeals

Dizal Receives $600 Million Upfront Payment from AstraZeneca as Global Sunvozertinib License Takes Effect – Only Dual‑Approved Oral TKI for EGFR Exon20ins NSCLC

Henlius Forms Strategic Partnership with Zhejiang Cancer Hospital to Advance High‑Quality Oncology Care in China
CompanyDeals

Henlius Forms Strategic Partnership with Zhejiang Cancer Hospital to Advance High‑Quality Oncology Care in China

Vcare Pharma Partners with CTTQ Subsidiary to Commercialize Eratrectinib – Next‑Generation TRK Inhibitor Approved in China for NTRK Fusion Solid Tumors
CompanyDeals

Vcare Pharma Partners with CTTQ Subsidiary to Commercialize Eratrectinib – Next‑Generation TRK Inhibitor Approved in China for NTRK Fusion Solid Tumors

CSPC Initiates Phase Ib Trial of JMT206 – First‑in‑Human Dual ActR‑IIA/IIB Monoclonal Antibody Targeting Weight Management with Muscle Preservation
CompanyDrug

CSPC Initiates Phase Ib Trial of JMT206 – First‑in‑Human Dual ActR‑IIA/IIB Monoclonal Antibody Targeting Weight Management with Muscle Preservation

Jiangsu Nhwa Signs Exclusive Global Licensing Deal with Somnivera – Clinical‑Stage Sleep‑Disorder Asset Backed by Up to US$517.5 Million in Potential Value
CompanyDeals

Jiangsu Nhwa Signs Exclusive Global Licensing Deal with Somnivera – Clinical‑Stage Sleep‑Disorder Asset Backed by Up to US$517.5 Million in Potential Value

MindRank Signs Exclusive Greater China Commercialization Deal With Sunshine Mandi for MDR‑001 – AI‑Designed Oral GLP‑1 Candidate in Phase III for Obesity, Worth Up to RMB 1.75 Billion
CompanyDeals

MindRank Signs Exclusive Greater China Commercialization Deal With Sunshine Mandi for MDR‑001 – AI‑Designed Oral GLP‑1 Candidate in Phase III for Obesity, Worth Up to RMB 1.75 Billion

NMPA Approves Lilly's Jaypirca (Pirtobrutinib) as First‑Line Monotherapy for CLL/SLL – Non‑Covalent BTK Inhibitor Completes Line‑of‑Therapy Progression in China
CompanyDrug

NMPA Approves Lilly’s Jaypirca (Pirtobrutinib) as First‑Line Monotherapy for CLL/SLL – Non‑Covalent BTK Inhibitor Completes Line‑of‑Therapy Progression in China

Sino Biopharmaceutical's CTTQ Partners With STADA on Pembrolizumab Biosimilar TQB3570 – Exclusive European License With Options Across Oncology and Immunology
CompanyDeals

Sino Biopharmaceutical’s CTTQ Partners With STADA on Pembrolizumab Biosimilar TQB3570 – Exclusive European License With Options Across Oncology and Immunology

Sinovac and Egypt's GENNVAX Launch sIPV Technical Cooperation Project in Beijing – Sabin Inactivated Polio Vaccine Localization Deal Enters Implementation Phase
CompanyDeals

Sinovac and Egypt’s GENNVAX Launch sIPV Technical Cooperation Project in Beijing – Sabin Inactivated Polio Vaccine Localization Deal Enters Implementation Phase